Abstract
Apoptosis is one of the main modalities of cell death, so important that it has outshined all others that only begin to be rediscovered. Apoptosis is an active, programmed way of cell death, implemented in response to intracellular or extracellular signals. Intracellular signals can originate from DNA lesions, mitosis defects, oxidative stress or other stresses, while extracellular signals correspond to death messages emitted by other cells. Apoptosis leads to the activation of proteases, called caspases, able to hydrolyse the cell constituents independently from the proteasome. Apoptosis plays many fundamental roles during embryology and tissue homoeostasis; to provide only one example, it is responsible for thymus regression during the passage from childhood to adulthood. Many authors have considered apoptosis as the obligate pathway to cell death induced by anticancer drugs, but in many cases it is only a phenotypic consequence, secondary to other mechanisms of drug-induced cell death, which only indirectly involve apoptosis. Apoptosis is often opposed to necrosis, but comparisons can also be made with senescence and mitotic cell death.
We present in this chapter the signalling pathways which lead to the execution of the cell death programme, but we neither describe the techniques that allow to detect or quantify apoptosis nor the execution of the apoptosis programme. In the first part, we present the most important proteins involved in apoptosis, from effectors to initiators. We present then the intracellular messages and the ‘intrinsic’ pathway that drive cells to death after they have undergone diverse types of stress and the extracellular signals that activate the ‘extrinsic’ pathway and drive cells to death on command. Various oncogenic alterations in apoptosis pathways have been identified, which lead to the identification of pharmacological targets.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420–30.
Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001–12.
Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ. 2007;14:56–65.
Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157–64.
Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.
Cory S, Adams JM. The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–56.
Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12:147–68.
Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193–209.
Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876–85.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109–24.
Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.
Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8:782–98.
Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–32.
Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18:1414–24.
Kruyt FAE. TRAIL and cancer therapy. Cancer Lett. 2008;263:14–25.
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252–75.
Lejeune FJ, Rüegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006;93:E90–100.
Lessene G, Czabotar PE, Colman P. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.
Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27:6194–206.
Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 2009;35:280–8.
Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol. 2008;76:939–46.
Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4:592–603.
Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553–62.
Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85–101.
Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16:360–7.
Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701–8.
Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398–406.
Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.
Yu JW, Shi Y. FLIP and the death effector domain family. Oncogene. 2008;27:6216–27.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Robert, J. (2015). Apoptosis Induction and Regulation. In: Textbook of Cell Signalling in Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-14340-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-14340-8_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14339-2
Online ISBN: 978-3-319-14340-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)